Nov 17, 2020 / 04:25PM GMT
Suranjit Mukherjee - Jefferies LLC, Research Division - Equity Associate
Hello, everyone. Welcome to the Virtual Jefferies London Healthcare Conference. My name is Jeet Mukherjee. I'm one of the Biotech Equity Research Associates here at Jefferies. And it's my pleasure to have Agenus here with us for this session. And speaking on their behalf is their President and COO, Jennifer Buell. So Jennifer, pleasure to have you with us.
Jennifer Buell - Agenus Inc. - President & COO
Jeet, thank you very much. We're thrilled to be here. Glad to connect. I'm glad to be part of the conference.
Questions and Answers:
Suranjit Mukherjee - Jefferies LLC, Research Division - Equity AssociateNot a problem. So Jennifer, to start things off, at a high level, I think it goes without saying that Agenus has quite a robust R&D pipeline, spanning from PD-1, CTLA-4, TIGIT, just to name a few. As a company, how are you guys prioritizing these assets going forward as they continue to advance in the clinic as well as other assets
Trustpilot
